or a recommendation by a qualified medical professional as defined by the law of the State in which the qualified medical professional is providing said prescription or recommendation. (B) Labeling For medical cannabis products provided pursuant to subparagraph (A), the Secretary shall issue labeling requirements in accord with section 7 of this Act. (6) No drug preclusion Notwithstanding any other law, section 301(ll) of the Federal Food, Drug, and Cosmetic Act, the drug preclusion rule, shall not apply to marihuana , as defined in section 102(16) of the Controlled Substances Act. Notwithstanding any other Federal law or provision of the Federal Food, Drug, and Cosmetic Act, the Food and Drug Administration shall treat cannabis without respect to the doctrine of drug preclusion. Nothing in this provision is meant to diminish or otherwise affect the ability of the Food and Drug Administration to regulate drug products (as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act), including those containing marihuana , (as defined in section 102(16) of the Controlled Substances Act) that are intended and marketed for use as a drug rather than a designated State medical cannabis product . (7) Rulemaking authority and timeline The Commissioner of the Food and Drug Administration, or their designee, shall implement the Act and enter formal rulemaking, consistent with the Administrative Procedure Act ( 5 U.S.C. 500 et seq. ), according to the following schedule: (A) Not later than 30 days after the date of enactment of this Act, publish in the Federal Register a Notice of Inquiry and Notice of Proposed Rulemaking for implementation of the Act, requesting public comment. (B) Not later than 60 days after the date of enactment of this Act— (i) issue an interim final rule for implementation and labeling regulations for certification of designated State products, and dietary supplements, food additives, cosmetics, and topicals containing cannabis